{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:06:46Z","timestamp":1794956806240,"version":"4.9.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>The rates of relapse and suicide risk are higher in treatment-resistant depression (TRD) vs non-treatment-resistant major depressive disorder. Even among patients with TRD who initially respond, the majority (70%) relapse within 6 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the long-term safety and efficacy of esketamine nasal spray, combined with an oral antidepressant, in patients with TRD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Phase 3, open-label, single-arm long-term extension study (SUSTAIN-3) conducted from June 2016 to December 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Outpatient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Adults with TRD who participated in \u22651 of 6 phase 3 \u201cparent\u201d studies continued esketamine by either entering a 4-week induction phase followed by an optimization\/maintenance phase of variable duration (n\u2005=\u2005458) or directly entering the optimization\/maintenance phase of SUSTAIN-3 (n\u2005=\u2005690), based on their individual response to study drug at the endpoint of the parent study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>Intranasal esketamine dosing was flexible, twice-weekly during induction and individualized to depression severity during optimization\/maintenance (weekly, every-other-week, or every-4-weeks), under direct supervision by site staff.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcomes and Measures<\/jats:title>\n                  <jats:p>To assess the long-term safety of esketamine. Efficacy endpoints included the change in depressive symptoms, assessed by the Montgomery-\u00c5sberg Depression Rating Scale (MADRS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1148 patients were enrolled. Total exposure to esketamine was 3777 cumulative patient-years. Mean (median, range) exposure to esketamine in SUSTAIN-3 was 42.9 (45.8, range 0-79) months. The most common adverse events were headache (36.9%), dizziness (33.9%), nausea (33.6%), dissociation (25.5%), nasopharyngitis (23.8%), somnolence (23.1%), dysgeusia (20.2%), and back pain (20.0%). During the study, 5.3% and 6.4% of participants discontinued due to lack of efficacy or adverse event, respectively. Nine participants died: COVID-19-related (n\u2005=\u20053), pneumonia (n\u2005=\u20052), and completed suicide, myocardial infarction, multiple injuries, unknown cause (n\u2005=\u20051 each). The mean MADRS total score decreased during induction, and this reduction persisted during optimization\/maintenance (mean [SD] change from baseline-to-phase endpoint of each phase: induction: \u221212.8 [9.73]; optimization\/maintenance:\u2005+\u20050.2 [9.93]). A total of 35.6% of participants were in remission at the induction endpoint, and 48.5% and 49.6% at week 112 and optimization\/maintenance endpoint, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions and Relevance<\/jats:title>\n                  <jats:p>In the SUSTAIN-3 final dataset, no new safety signals were identified during long-term treatment with intermittently-dosed esketamine, combined with oral antidepressant, and improvement in depression generally persisted among participants who remained on maintenance treatment. These results add to the accumulated evidence on TRD treatment with esketamine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial Registration<\/jats:title>\n                  <jats:p>clinicaltrials.gov identifier: NCT02782104.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaf027","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:12:32Z","timestamp":1746335552000},"source":"Crossref","is-referenced-by-count":47,"title":["Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9695-2630","authenticated-orcid":false,"given":"Naim","family":"Zaki","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li (Nancy)","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Doherty","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C","family":"Drevets","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson , San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9681-8780","authenticated-orcid":false,"given":"Randall L","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3722-8829","authenticated-orcid":false,"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine , New Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine , New Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H","family":"Young","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Acioly L T","family":"Lacerda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Federal University of Sao Paulo , Sao Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Woo","family":"Paik","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kyung Hee University, College of Medicine , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina","family":"Popova","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson , Beerse ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,4]]},"reference":[{"key":"2025062619240551500_CIT0001","volume-title":"Practice Guideline for the Treatment of Patients with Major Depressive Disorder","author":"American Psychiatric Association","year":"2013","edition":"3rd ed"},{"key":"2025062619240551500_CIT0002","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/ijnp\/pyy009","article-title":"Major depression and the degree of suicidality: results of the European group for the study of resistant depression (GSRD)","volume":"21","author":"Dold","year":"2018","journal-title":"Int J Neuropsychopharmacol."},{"key":"2025062619240551500_CIT0003","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry."},{"key":"2025062619240551500_CIT0004","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1176\/ajp.2007.164.2.201","article-title":"STAR*D: what have we learned","volume":"164","author":"Rush","year":"2007","journal-title":"Am J Psychiatry."},{"key":"2025062619240551500_CIT0005","author":"United States Food & Drug Administration"},{"key":"2025062619240551500_CIT0006","author":"European Medicines Agency"},{"key":"2025062619240551500_CIT0007","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry."},{"key":"2025062619240551500_CIT0008","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol."},{"key":"2025062619240551500_CIT0009","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am J Geriatr Psychiatry."},{"key":"2025062619240551500_CIT0010","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry."},{"key":"2025062619240551500_CIT0011","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2025062619240551500_CIT0012","doi-asserted-by":"publisher","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"2025062619240551500_CIT0013","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","article-title":"Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study","volume":"48","author":"Zaki","year":"2023","journal-title":"Neuropsychopharmacology."},{"key":"2025062619240551500_CIT0014","author":"National Library of Medicine"},{"key":"2025062619240551500_CIT0015","volume-title":"ECDEU Assessment Manual for Psychopharmacology.","author":"Guy","year":"1976"},{"key":"2025062619240551500_CIT0016","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA\u2019s pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am J Psychiatry."},{"key":"2025062619240551500_CIT0017","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/arclin\/acp010","article-title":"Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex","volume":"24","author":"Maruff","year":"2009","journal-title":"Arch Clin Neuropsychol."},{"key":"2025062619240551500_CIT0018","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.acn.2008.03.002","article-title":"An examination of the construct validity and factor structure of the Groton Maze Learning Test, a new measure of spatial working memory, learning efficiency, and error monitoring","volume":"23","author":"Pietrzak","year":"2008","journal-title":"Arch Clin Neuropsychol."},{"key":"2025062619240551500_CIT0019","volume-title":"Hopkins Verbal Learning Test - Revised, Professional Manual.","author":"Brandt","year":"2007"},{"key":"2025062619240551500_CIT0020","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry."},{"key":"2025062619240551500_CIT0021","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. patient health questionnaire","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA."},{"key":"2025062619240551500_CIT0022","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2190\/T8EM-C8YH-373N-1UWD","article-title":"Assessing psychiatric impairment in primary care with the Sheehan Disability Scale","volume":"27","author":"Leon","year":"1997","journal-title":"Int J Psychiatry Med."},{"key":"2025062619240551500_CIT0023","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1176\/appi.ps.201900295","article-title":"Defining success in measurement-based care for depression: a comparison of common metrics","volume":"71","author":"Coley","year":"2020","journal-title":"Psychiatr Serv."},{"key":"2025062619240551500_CIT0024","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale","volume":"23","author":"Sheehan","year":"2008","journal-title":"Int Clin Psychopharmacol."},{"key":"2025062619240551500_CIT0025","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euroneuro.2024.05.009","article-title":"Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression","volume":"85","author":"McIntyre","year":"2024","journal-title":"Eur Neuropsychopharmacol."},{"key":"2025062619240551500_CIT0026","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J Affect Disord."},{"key":"2025062619240551500_CIT0027","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2024\/7262794","article-title":"Use of esketamine nasal spray in patients with treatment-resistant depression in routine practice: a real-world French study","volume":"1","author":"Samalin","year":"2024","journal-title":"Depress Anxiety."},{"key":"2025062619240551500_CIT0028","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/15563650.2024.2380773","article-title":"Can mind-altering prescription medicines be safe? Lessons from ketamine and esketamine","volume":"62","author":"Dart","year":"2024","journal-title":"Clin Toxicol (Phila)"},{"key":"2025062619240551500_CIT0029","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jad.2021.11.004","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: Healthcare resource utilization","volume":"298","author":"Heerlein","year":"2022","journal-title":"J Affect Disord."},{"key":"2025062619240551500_CIT0030","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3111\/13696998.2012.724745","article-title":"Medicare patient experience with vagus nerve stimulation for treatment-resistant depression","volume":"16","author":"Feldman","year":"2013","journal-title":"J Med Econ"},{"key":"2025062619240551500_CIT0031","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jad.2018.06.030","article-title":"Mortality in treatment-resistant unipolar depression: a register-based cohort study in Sweden","volume":"238","author":"Reutfors","year":"2018","journal-title":"J Affect Disord."},{"key":"2025062619240551500_CIT0032","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jad.2018.04.016","article-title":"Treatment-resistant depression and suicidality","volume":"235","author":"Bergfeld","year":"2018","journal-title":"J Affect Disord."},{"key":"2025062619240551500_CIT0033","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1176\/appi.ajp.2019.19070688","article-title":"Comment on a word to the wise about intranasal esketamine","volume":"176","author":"Drevets","year":"2019","journal-title":"Am J Psychiatry."},{"key":"2025062619240551500_CIT0034","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1017\/S2045796020000268","article-title":"Comment to Drs. Gastaldon, Papola, Ostuzzi and Barbui","volume":"29","author":"Mathews","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2025062619240551500_CIT0035","doi-asserted-by":"publisher","first-page":"e3171","DOI":"10.1002\/brb3.3171","article-title":"Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone","volume":"13","author":"Kern","year":"2023","journal-title":"Brain Behav"},{"key":"2025062619240551500_CIT0036","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/13803395.2015.1136598","article-title":"Comparing individual differences in inconsistency and plasticity as predictors of cognitive function in older adults","volume":"38","author":"Grand","year":"2016","journal-title":"J Clin Exp Neuropsychol."},{"key":"2025062619240551500_CIT0037","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1017\/S0033291715000926","article-title":"Neurocognitive intra-individual variability in mood disorders: effects on attentional response time distributions","volume":"45","author":"Gallagher","year":"2015","journal-title":"Psychol Med."},{"key":"2025062619240551500_CIT0038","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/archgenpsychiatry.2010.184","article-title":"Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy","volume":"68","author":"Reynolds","year":"2011","journal-title":"Arch Gen Psychiatry."},{"key":"2025062619240551500_CIT0039","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.euroneuro.2024.12.013","article-title":"Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study","volume":"93","author":"Vieta","year":"2025","journal-title":"Eur Neuropsychopharmacol."}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf027\/63051805\/pyaf027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/6\/pyaf027\/63051805\/pyaf027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/6\/pyaf027\/63051805\/pyaf027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T23:24:14Z","timestamp":1750980254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf027\/8124703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,4]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf027","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,4]]},"article-number":"pyaf027"}}